^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G12D + STK11 mutation

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog, Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19
    Entrez ID:
    3845; 6794
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    over1year
    Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC. (PubMed, JTO Clin Res Rep)
    Co-occurring mutations were common in patients with KRAS G12D-mutant NSCLC. STK11 and KEAP1 co-mutations were associated with worse clinical outcomes, whereas co-occurring TP53 did not affect survival.
    Journal • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • KRAS G12D • STK11 mutation • KEAP1 mutation • KRAS G12 • KRAS G12D + STK11 mutation